PRME (Prime Medicine, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PRME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | David P Schenkein | Director | A | — | — |
| 2026-06-08 | Thomas Cahill | Director | A | — | — |
| 2026-06-08 | Wendy Chung | Director | A | — | — |
| 2026-06-08 | ROBERT NELSEN | Director | A | — | — |
| 2026-06-08 | Jeffrey D Marrazzo | Director | A | — | — |
| 2026-06-08 | Kaye I Foster-Cheek | Director | A | — | — |
| 2026-06-08 | Michael Aaron Kelly | Director | A | — | — |
| 2026-04-17 | Svetlana Ni Makhni | Chief Financial Officer | A | — | — |
| 2026-02-27 | Allan Reine | Chief Executive Officer | A | — | — |
| 2026-02-24 | ANN L. LEE | Chief Technical Officer | A | — | — |
| 2026-02-24 | Carman Alenson | See Remarks | A | — | — |
| 2025-08-05 | ROBERT NELSEN | Director | MIXED | — | — |
| 2025-08-05 | Michael Aaron Kelly | Director | MIXED | — | — |
| 2025-08-05 | David P Schenkein | Director | MIXED | — | — |
| 2025-08-05 | Allan Reine | Chief Executive Officer | MIXED | — | — |
| 2025-08-05 | Carman Alenson | See Remarks | MIXED | — | — |
| 2025-08-05 | Wendy Chung | Director | MIXED | — | — |
| 2025-08-05 | Kaye I Foster-Cheek | Director | MIXED | — | — |
| 2025-08-05 | Thomas Cahill | Director | MIXED | — | — |
| 2025-08-05 | ANN L. LEE | Chief Technical Officer | MIXED | — | — |
| 2025-08-05 | Jeffrey D Marrazzo | Director | MIXED | — | — |
| 2025-08-05 | GV 2021, L.P. | 10%+ Owner | Buy | — | — |
| 2025-08-01 | ARCH Venture Partners X, LLC | 10%+ Owner | Buy | — | — |
| 2025-08-01 | ROBERT NELSEN | Director | Buy | — | — |
| 2025-08-01 | ARCH Venture Fund XII, L.P. | 10%+ Owner | Buy | — | — |
| 2025-07-01 | David R. Liu | 10%+ Owner | Buy | — | — |
| 2025-06-23 | David R. Liu | 10%+ Owner | Buy | — | — |
| 2025-06-16 | David R. Liu | 10%+ Owner | Buy | — | — |
| 2025-06-12 | David R. Liu | 10%+ Owner | Buy | — | — |
| 2025-06-05 | Thomas Cahill | Director | A | — | — |
| 2025-06-05 | Kaye I Foster-Cheek | Director | A | — | — |
| 2025-06-05 | ROBERT NELSEN | Director | A | — | — |
| 2025-06-05 | Michael Aaron Kelly | Director | A | — | — |
| 2025-06-05 | David P Schenkein | Director | A | — | — |
| 2025-06-05 | Wendy Chung | Director | A | — | — |
| 2025-06-05 | Jeffrey D Marrazzo | Director | A | — | — |
| 2025-05-22 | Richard Brudnick | Chief Business Officer | Buy | — | — |
| 2025-05-22 | Allan Reine | Chief Executive Officer | Buy | — | — |
| 2025-05-22 | ANN L. LEE | Chief Technical Officer | Buy | — | — |
| 2025-05-19 | Jeffrey D Marrazzo | Director | A | — | — |
| 2025-05-19 | Allan Reine | Chief Executive Officer | A | — | — |
| 2025-05-12 | Keith Michael Gottesdiener | See Remarks | A | — | — |
| 2025-05-12 | Allan Reine | Chief Financial Officer | A | — | — |
| 2025-05-12 | ANN L. LEE | Chief Technical Officer | A | — | — |
| 2025-03-04 | Keith Michael Gottesdiener | See Remarks | A | — | — |
| 2025-03-03 | ANN L. LEE | Chief Technical Officer | A | — | — |
| 2025-03-03 | Meredith Goldwasser | SVP, Strategy & Corporate Ops. | A | — | — |
| 2025-03-03 | Richard Brudnick | Chief Business Officer | A | — | — |
| 2025-03-03 | Allan Reine | Chief Financial Officer | A | — | — |
| 2025-03-03 | Jeremy Duffield | Chief Scientific Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 20,240,945 | — |
| — | 10%+ Owner | 10,557,092 | — |
| — | 10%+ Owner | 10,318,420 | — |
| — | 10%+ Owner | 10,229,657 | — |
| — | 10%+ Owner | 6,230,300 | — |
| — | 10%+ Owner | 6,230,300 | — |
| — | 10%+ Owner | 6,128,297 | — |
| — | 10%+ Owner | 6,128,297 | — |
| — | 10%+ Owner | 6,128,297 | — |
| — | Director | 6,128,297 | — |
| — | Director | 4,905,679 | — |
| — | 10%+ Owner | 3,262,440 | — |
| — | See Remarks | 2,361,078 | — |
| — | 10%+ Owner | 1,762,440 | — |
| — | Chief Executive Officer | 125,000 | — |
| — | Chief Technical Officer | 100,000 | — |
| — | — | 98,967 | — |
| — | Chief Business Officer | 20,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PRME quote page; the site-wide leaderboard is on the insider transactions hub.